A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis

Conditions

• Bronchiectasis

Eligibility Criteria

Sex

ALL

Age

18 Years - 85 Years

Healthy Volunteers

Not accepted

Interventions

• GSK3862995B — DRUG
  Participants will be administered with dose level 1 of GSK3862995B.
• Placebo — DRUG
  Participants will be administered with matching placebo.

Study Details

This study is designed to find out how effective and safe a new drug, GSK3862995B, is for adult participants with bronchiectasis, a chronic lung disease. The study will also test how the body processes the drug and to check for any immune reactions. Participants will be divided into groups randomly to receive either one of two different doses of the study drug or a placebo. The main goal of the study is to see how well the drug works compared to the placebo in helping those with bronchiectasis.

Key Dates

First listed

Oct 1, 2025

Start date

Oct 30, 2025

Status verified

Aug 2026

Primary completion

May 4, 2027

Completion

Dec 10, 2027

Study Design

Enrollment

363 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: GSK3862995B Dose Level 1
  Participants will receive GSK3862995B Dose level 1.
• Experimental: GSK3862995B Dose Level 2
  Participants will receive GSK3862995B Dose level 2.
• Placebo Comparator: Placebo
  Participants will receive matching placebo.

Primary Outcome Measure

Annualized rate of Exacerbations for GSK3862995B Dose Level 1 Following Repeat Doses Compared with Placebo [ Time Frame: Up to Week 48 ]

Central Contacts

• US GSK Clinical Trials Call Center
  877-379-3718
  [email protected]
• EU GSK Clinical Trials Call Center
  +44 (0) 20 89904466
  [email protected]

Locations (31)

Find similar trials in Mobile, AL

Related Studies

• Natural History of Bronchiectasis
  Recruiting · National Heart, Lung, and Blood Institute (NHLBI) · Bethesda, Maryland
• Evaluation Of The Lung Microbiome In NTM Bronchiectasis
  Recruiting · NYU Langone Health · New York, New York
• Hypertonic Saline in NCFB
  PHASE4 · Recruiting · University of North Carolina, Chapel Hill · Chapel Hill, North Carolina
• Acoustic Waveform Respiratory Evaluation
  Recruiting · Indiana University · Indianapolis, Indiana